Amgen to Acquire Micromet for $11 per Share Totaling $1.16B

Amgen (NASDAQ:

) and Micromet, Inc. (NASDAQ:

) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash. The transaction, which values Micromet at approximately $1.16 billion, was unanimously approved by both the Amgen and Micromet Boards of Directors.